Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.28 -0.1  -2.6%

Last Trade - 09/04/21

Small Cap
Market Cap £164.3m
Enterprise Value £153.0m
Revenue £2.71m
Position in Universe 764th / 1831

Results of rights issue − Offering fully subscribed

Thu 15th October, 2020 7:50am
For best results when printing this announcement, please click on link below:

October 15, 2020 
Announcement no. 18

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in or into the United
States, Canada, Australia or Japan or any jurisdiction in which such
publication or distribution is unlawful. This announcement does not constitute
or form a part of any offer to sell or solicitation of an offer to purchase or
subscribe for securities in United States, Canada, Australia or Japan or any
other jurisdiction in which it would be unlawful to do so. Any failure to
comply with this may constitute a violation of US, Canadian, Australian or
Japanese securities laws or the securities laws of other states as the case
may be. Any securities described herein may not be offered or sold in the
United States absent registration or an exemption from registration; any
public offering of securities to be made in the United States will be made by
means of a prospectus that may be obtained from the company that will contain
detailed information about the company and management, as well as financial

Results of rights issue − Offering fully subscribed

By company announcement no. 17 on September 25, 2020, BioPorto A/S
(“BioPorto” or the “Company”) announced the initiation of a
fully-guaranteed rights issue (the “Offering”) with pre-emptive
subscription rights for the Company’s existing shareholders allowing for
subscription of up to 66,645,476 new shares with a nominal value of DKK 1 each
(the “New Shares”).

The subscription period for the New Shares has expired, and BioPorto is
pleased to announce that all of the New Shares have been subscribed for.
64,989,801 of the New Shares (equivalent to 97.5%) have been subscribed for by
exercise of pre-emptive subscription rights. As demand for the remaining
shares has exceeded the number of New Shares not subscribed for by exercise of
pre-emptive subscription rights, the remaining shares have been allocated as
described in the prospectus. Investors who have been allocated these remaining
shares will be informed individually.

The Company expects to complete the Offering when payment of subscription
amounts has taken place and the New Shares have been registered with the
Danish Business Authority, expectedly on October 21, 2020. As soon as possible
thereafter, the New Shares will be admitted to trading and official listing on
Nasdaq Copenhagen A/S under the Company’s permanent ISIN-code
(DK0011048619), expectedly no later than October 22, 2020.

As stated in company announcement no. 17 on September 25, 2020, the Offering
may be withdrawn at any time prior to the registration of the capital increase
relating to the Offering with the Danish Business Authority. Any such
withdrawal would be notified via Nasdaq Copenhagen A/S.

The expected timetable for the Offering remains unchanged.

Global Coordinator and legal advisors 
Nordea is acting as Global Coordinator of the Offering.

Gorrissen Federspiel acts as legal advisor to the Company. Kromann Reumert
acts as legal advisor to the Global Coordinator.

For further information, please contact: 
Peter Mørch Eriksen, CEO 
Ole Larsen, CFO 
Telephone +45 4529 0000, e-mail:

About BioPorto 
BioPorto is an in vitro diagnostics company that provides tests and antibodies
to clinicians and researchers around the world. We use our antibody and assay
expertise to transform novel research tools into clinically actionable
biomarkers that can make a difference in patients’ lives. BioPorto is
headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen
stock exchange  CPH:BIOPOR .

Forward-looking statement disclaimer:
Certain statements in this announcement are forward-looking statements, which
are based on the Company’s expectations, intentions and projections
regarding its future performance, anticipated events or trends and other
matters that are not historical facts, including with respect to the timing,
terms and consummation of the rights issue described herein and potential FDA
clearance and commercialization of The NGAL Test. These forward-looking
statements, which may use words such as “aim”, “anticipate”,
“believe”, “intend”, “estimate”, “expect” and words of similar
meaning, include all matters that are not historical facts. These
forward-looking statements involve risks, and uncertainties that could cause
the actual results of operations, financial condition, liquidity, dividend
policy and the development of the industry in which the company’s business
operates to differ materially from the impression created by the
forward-looking statements. These statements are not guarantees of future
performance and are subject to known and unknown risks, uncertainties and
other factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements. Given these risks and
uncertainties, prospective investors are cautioned not to place undue reliance
on forward-looking statements. Forward-looking statements speak only as of the
date of such statements and, except as required by applicable law, BioPorto
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or

*     2020 10 15 Announcement no. 18
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.